SCHEMBL3603569

SCHEMBL3603569

Cc1ccc(-c2cccc3c2ccn3CC(=O)NCCN(C)C2CCCCC2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.41
THRB P10828 1/20 0.41
GAA P10253 1/20 0.40
TSHR P16473 1/20 0.40
KMT2A Q03164 4/20 0.39
MEN1 O00255 2/20 0.39
NPSR1 Q6W5P4 1/20 0.38
TP53 P04637 3/20 0.38
RXFP1 Q9HBX9 1/20 0.37
GRIN2B Q13224 1/20 0.36
KDM4E B2RXH2 1/20 0.36
USP2 O75604 1/20 0.36
MAPK1 P28482 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
ALDH1A1 P00352 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
NPC1 O15118 1/20 0.35
BCHE P06276 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3595659 0.92 MEN1 (0.41) MAPTTHRBGAATSHRKMT2A
SCHEMBL3598309 0.87 SMN1; SMN2 (0.43) MAPTTHRBGAATSHRKMT2A
SCHEMBL3594706 0.85 GAA (0.42) MAPTGAATSHRKMT2AMEN1
SCHEMBL13116000 0.84 GRIN2B (0.43) MAPTTHRBGAATSHRKMT2A
SCHEMBL3603866 0.84 MEN1 (0.45) MAPTGAATSHRKMT2AMEN1
SCHEMBL3603572 0.83 MAPT (0.42) MAPTTHRBTSHRKMT2AMEN1
SCHEMBL3596255 0.81 NPC1 (0.46) MAPTKMT2ATP53GRIN2BNPC1
SCHEMBL3602466 0.81 KDM4E (0.44) MAPTGAATSHRKMT2ANPSR1
SCHEMBL13115718 0.81 GRIN2B (0.40) MAPTTSHRKMT2AMEN1NPSR1
SCHEMBL3591923 0.80 GRIN2B (0.44) GAATSHRKMT2ANPSR1RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
WO-2007115231-A2 CXCR4 MODULATORS CHEMOCENTRYX, INC. (US) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275965-A1 CXCR4 modulators CXCL12, CXCR4, CXCR1 MAPT 2809/4885THRB 1690/4885GAA 1982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.